Chronic infection with hepatitis B virus (HBV) greatly increases the risk for liver cirrhosis and
hepatocellular carcinoma (HCC). HBV isolates worldwide can be divided into ten genotypes …

Patients with chronic hepatitis B (CHB) can be successfully treated using nucleos (t) ide
analogs (NA), but drug-resistant hepatitis B virus (HBV) mutants frequently arise, leading to …

Large volume of new data on the natural history and treatment of chronic hepatitis B virus
(HBV) infection have become available since 2008. These include further studies in …

Background The effectiveness of antiviral therapy in preventing disease progression in
patients with chronic hepatitis B and advanced fibrosis or cirrhosis is unknown. Methods …

Diseases (AASLD) also presented and continued to revise their clinical practice guidelines,
and the latest updates were in 2015, 2017, and 2018. However, since the medical …

Patients with chronic hepatitis B virus (HBV) infection who develop antiviral resistance lose
benefits of therapy and may be predisposed to further resistance. Entecavir (ETV) resistance …

More than 400 million people worldwide are chronically infected by the hepatitis B virus. The
virus is responsible for more than 300000 cases of liver cancer every year and for similar …

Background Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a
key therapeutic goal for chronic hepatitis B. Methods In this double-blind, phase 3 trial, 1370 …

BACKGROUND & AIMS: The GLOBE trial has compared the efficacy and safety of
telbivudine versus lamivudine treatment over 2 years in patients with chronic hepatitis B …

Background & aims: Data on thelong-term safety of lamivudine are limited. The aim of this
analysis was to determine the incidence of hepatitis flares, hepatic decompensation, and …